Premium
Lansoprazole versus famotidine: efficacy and tolerance in the acute management of duodenal ulceration
Author(s) -
HOTZ J.,
KLEINERT R.,
GRYMBOWSKI T.,
HENNIG U.,
SCHWARZ J. A.
Publication year - 1992
Publication title -
alimentary pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 3.308
H-Index - 177
eISSN - 1365-2036
pISSN - 0269-2813
DOI - 10.1111/j.1365-2036.1992.tb00548.x
Subject(s) - lansoprazole , famotidine , antacid , medicine , gastroenterology , concomitant , duodenal ulcer , randomized controlled trial , proton pump inhibitor , omeprazole
SUMMARY Lansoprazole (AG 1749/CG 4801) is an inhibitor of gastric acid secretion by blocking H + ,K + ‐ATPase. In this 2:1 randomized, double‐blind, multicentre trial lansoprazole 30 mg am was compared to 40 mg famotidine nocte in 264 out‐patients suffering from uncomplicated duodenal ulcer. After 2 weeks of treatment ulcer healing was confirmed endoscopically in a significantly higher proportion ( P = 0.027) of patients treated with lansoprazole (94/174 = 54.0%) compared to patients receiving famotidine (35/90 = 38.9%). Cumulative healing rates after 4 weeks were 91.4% for the lansoprazole group and 83.3% for the famotidine group ( P = 0.065). Pain relief and decrease of concomitant antacid consumption during treatment were comparable in both groups. Both compounds were well tolerated. Rates of recurrent duodenal ulcer in the 6 months after trial treatment were 45/158 (28.5%) after lansoprazole, and 18/69 (26.1%) after famotidine.